Neurogene Inc (NGNE) - Total Liabilities
Based on the latest financial reports, Neurogene Inc (NGNE) has total liabilities worth $25.36 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Neurogene Inc - Total Liabilities Trend (2011–2025)
This chart illustrates how Neurogene Inc's total liabilities have evolved over time, based on quarterly financial data. See how liquid is Neurogene Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
Neurogene Inc Competitors by Total Liabilities
The table below lists competitors of Neurogene Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tianjin Jinbin Development
SHE:000897
|
China | CN¥1.31 Billion |
|
Ovid Therapeutics Inc
NASDAQ:OVID
|
USA | $20.27 Million |
|
Tsogo Sun
JSE:TSG
|
South Africa | ZAC9.74 Billion |
|
Prince Housing & Development Corp
TW:2511
|
Taiwan | NT$21.20 Billion |
|
Suli Co Ltd
SHG:603585
|
China | CN¥2.18 Billion |
|
Yungshin Construction & Development Co Ltd
TWO:5508
|
Taiwan | NT$13.75 Billion |
|
Zuming Bean Products Co Ltd
SHE:003030
|
China | CN¥1.36 Billion |
|
Dezhou United Petroleum Technology Co.Ltd.
SHE:301158
|
China | CN¥450.62 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Neurogene Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Neurogene Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Neurogene Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Neurogene Inc (2011–2025)
The table below shows the annual total liabilities of Neurogene Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $23.72 Million | -6.46% |
| 2024-12-31 | $25.36 Million | -30.63% |
| 2023-12-31 | $36.55 Million | +243.57% |
| 2022-12-31 | $10.64 Million | -94.50% |
| 2021-12-31 | $193.36 Million | +901.72% |
| 2020-12-31 | $19.30 Million | +261.75% |
| 2019-12-31 | $5.34 Million | +7.89% |
| 2018-12-31 | $4.95 Million | -56.77% |
| 2017-12-31 | $11.44 Million | +17.76% |
| 2016-12-31 | $9.72 Million | +97.36% |
| 2015-12-31 | $4.92 Million | -6.68% |
| 2014-12-31 | $5.28 Million | -29.51% |
| 2013-12-31 | $7.48 Million | +409.83% |
| 2012-12-31 | $1.47 Million | +13.13% |
| 2011-12-31 | $1.30 Million | -- |
About Neurogene Inc
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disea… Read more